skip to main content

H.R. 321: Neuromyelitis Optica Consortium Act

We don’t have a summary available yet.

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress, and was published on Jan 8, 2019.

Neuromyelitis Optica Consortium Act

This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis.

The consortium must

award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO; assemble a panel of experts to provide guidance and recommendations on research design and protocols; and designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.